Octamer Transcription Factor-3
"Octamer Transcription Factor-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An octamer transcription factor that is expressed primarily in totipotent embryonic STEM CELLS and GERM CELLS and is down-regulated during CELL DIFFERENTIATION.
| Descriptor ID |
D050814
|
| MeSH Number(s) |
D12.776.260.655.500.300 D12.776.930.710.500.300
|
| Concept/Terms |
Octamer Transcription Factor-3- Octamer Transcription Factor-3
- Octamer Transcription Factor 3
- Transcription Factor-3, Octamer
- POU5F1 Transcription Factor
- Transcription Factor, POU5F1
- POU Domain, Class 5, Transcription Factor 1
- Oct-3 Transcription Factor
- Oct 3 Transcription Factor
- Transcription Factor, Oct-3
- Transcription Factor Oct-3
- Oct-3, Transcription Factor
- Transcription Factor Oct 3
- Transcription Factor Oct-4
- Oct-4, Transcription Factor
- Transcription Factor Oct 4
- Octamer-Binding Protein 4
- Octamer Binding Protein 4
- Oct-4 Transcription Factor
- Oct 4 Transcription Factor
- Transcription Factor, Oct-4
|
Below are MeSH descriptors whose meaning is more general than "Octamer Transcription Factor-3".
Below are MeSH descriptors whose meaning is more specific than "Octamer Transcription Factor-3".
This graph shows the total number of publications written about "Octamer Transcription Factor-3" by people in this website by year, and whether "Octamer Transcription Factor-3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Octamer Transcription Factor-3" by people in Profiles.
-
He XD, Phillips S, Hioki K, Majhi PD, Babbitt C, Tremblay KD, Pobezinsky LA, Mager J. TATA-binding associated factors have distinct roles during early mammalian development. Dev Biol. 2024 Jul; 511:53-62.
-
Wallingford MC, Hiller J, Zhang K, Mager J. YY1 Is Required for Posttranscriptional Stability of SOX2 and OCT4 Proteins. Cell Reprogram. 2017 08; 19(4):263-269.
-
Kapinas K, Kim H, Mandeville M, Martin-Buley LA, Croce CM, Lian JB, van Wijnen AJ, Stein JL, Altieri DC, Stein GS. microRNA-mediated survivin control of pluripotency. J Cell Physiol. 2015 Jan; 230(1):63-70.
-
Kearns NA, Genga RM, Enuameh MS, Garber M, Wolfe SA, Maehr R. Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. Development. 2014 Jan; 141(1):219-23.
-
Santoni FA, Guerra J, Luban J. HERV-H RNA is abundant in human embryonic stem cells and a precise marker for pluripotency. Retrovirology. 2012 Dec 20; 9:111.
-
Patel SA, Ramkissoon SH, Bryan M, Pliner LF, Dontu G, Patel PS, Amiri S, Pine SR, Rameshwar P. Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci Rep. 2012; 2:906.
-
Mullen AC, Orlando DA, Newman JJ, Lov?n J, Kumar RM, Bilodeau S, Reddy J, Guenther MG, DeKoter RP, Young RA. Master transcription factors determine cell-type-specific responses to TGF-? signaling. Cell. 2011 Oct 28; 147(3):565-76.
-
Zhong B, Trobridge GD, Zhang X, Watts KL, Ramakrishnan A, Wohlfahrt M, Adair JE, Kiem HP. Efficient generation of nonhuman primate induced pluripotent stem cells. Stem Cells Dev. 2011 May; 20(5):795-807.
-
Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA, de Jong S. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 2010 Oct; 120(10):3594-605.
-
Orlova KA, Tsai V, Baybis M, Heuer GG, Sisodiya S, Thom M, Strauss K, Aronica E, Storm PB, Crino PB. Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias. J Neuropathol Exp Neurol. 2010 Aug; 69(8):850-63.